Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $16.5252W HIGH $25.14
Volume
507.58 K
Value Traded
18.13 M
Short % Float
10.02%
+2.76%Week
+2.66%1 Month
-4.5%3 Month
-11.51%6 Month
+70.15%5 Year
+46.75%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.53 B
EPS (TTM)
4.94
P/E Ratio
4.29
Ent. Value
1.22 B
Total Shares
72.25 M
Float Shares
71.32 M
Insiders
1.28%
Institutions
104.14%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
INVA Catalyst Timeline
Dated clinical, regulatory and corporate events for Innoviva, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Innoviva, Inc.
248Total events
1Upcoming
86Tier-1 (high impact)
2013 to 2026Coverage
Event history 50
▲Other Regulator MilestoneEx-US Regulatory
XACDURO, ZEVTERA, and NUZOLVENCE designated finalists for 2026 Prix Galien USA Award
▲Product LaunchNUZOLVENCE®ApprovedPost-Market
NUZOLVENCE® available to patients
uncomplicated urogenital gonorrheasource ↗
▲Partnership / LicenseXACDUROApprovedCorporate
Distribution and licensing agreement with Dr. Reddy's for XACDURO in select international markets
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat
▲Product LaunchNUZOLVENCE®ApprovedPost-Market
NUZOLVENCE® available to patients
uncomplicated urogenital gonorrheasource ↗
▲Partnership / LicenseXACDUROApprovedCorporate
Innoviva Specialty Therapeutics enters exclusive distribution and licensing agreement with Dr. Reddy's Laboratories for XACDURO in South and Central America, the Caribbean, Russia and CIS countries
hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)source ↗
▲Product LaunchPost-Market
Innoviva launches Nortiva Bio, a wholly owned subsidiary to advance the LYNX long-acting oral drug delivery platform
▲Equity OfferingCorporate
Innoviva repurchased 1,403,247 shares for $31.4 million under its $125 million share repurchase program
●Milestone PaymentCorporate
Innoviva continued to support companies in its strategic healthcare asset portfolio with $55.0 million aggregate capital commitment
▲FDA ApprovalNUZOLVENCE®ApprovedFDA Decision
FDA approval of NUZOLVENCE for uncomplicated urogenital gonorrhea
uncomplicated urogenital gonorrheasource ↗
◆PDUFA DatezoliflodacinApprovedRegulatory Filing
PDUFA target action date set for December 15, 2025
uncomplicated gonorrheasource ↗
▲FDA ApprovalNUZOLVENCE®ApprovedFDA Decision
FDA approval of NUZOLVENCE®
uncomplicated urogenital gonorrheasource ↗
▲NDA SubmissionzoliflodacinApprovedRegulatory Filing
Zoliflodacin NDA accepted by FDA with Priority Review
uncomplicated gonorrheasource ↗
▲Product LaunchZEVTERAPost-Market
ZEVTERA launched in the U.S.
MRSA-related Staphylococcus aureus bacteremiasource ↗
●Timing GuidancezoliflodacinApprovedPresentation
NDA filing for zoliflodacin on track
uncomplicated gonorrheasource ↗
●Timing GuidancezoliflodacinApprovedPresentation
NDA submission for zoliflodacin expected in early 2025
uncomplicated gonorrheasource ↗
▲Partnership / LicenseZEVTERACorporate
Exclusive U.S. commercialization and distribution rights to ZEVTERA acquired from Basilea
▲FDA ApprovalXACDUROApprovedFDA Decision
XACDURO approved in China
hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complexsource ↗
▲Oral PresentationzoliflodacinApprovedPresentation
Phase 3 zoliflodacin data highlighted at ESCMID Global 2024
uncomplicated gonorrheasource ↗
▲Primary Endpoint MetzoliflodacinApprovedClinical Data
Zoliflodacin met primary efficacy endpoint in Phase 3 trial
uncomplicated gonorrheasource ↗
▲Topline ReadoutzoliflodacinApprovedClinical Data
Announced positive topline Phase 3 data for zoliflodacin
uncomplicated gonorrheasource ↗
▲Product LaunchXACDUROApprovedPost-Market
Launched XACDURO in the United States
hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by Acinetobactersource ↗
▲FDA ApprovalXACDUROApprovedFDA Decision
FDA approval for XACDURO
hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobactersource ↗
▲Milestone PaymentXACDUROApprovedCorporate
Milestone payment from partner for FDA approval of XACDURO
▲Partnership / LicenseCorporate
Credit and security agreement with Armata Pharmaceuticals and $25M investment
▲FDA ApprovalXACDUROApprovedFDA Decision
FDA approval of XACDURO
hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complexsource ↗
▲AdCom OutcomeSulbactam-durlobactamAdvisory Committee
FDA Antimicrobial Drugs Advisory Committee unanimous vote in support of approval for sulbactam-durlobactam
hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumoniasource ↗
Past FDA Catalysts and PDUFA Decisions
How INVA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-12 | Zoliflodacin (spiropyrimidinetrione oral antibiotic) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$127M
Pipeline Value
$1.0B
Commercial Value
Overvalued
Valuation Signal
6
Drugs Scored
0.3x
rNPV / MCap
Top 44%
Micro Cap(rank 291 of 660)
Percentile Rank
Innoviva, Inc. faces pipeline headwinds (38/100), with $317M risk-adjusted pipeline value, led by Angiotensin II in Liver Transplant; Complications (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $440M x 2.4 = $1.0B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| XACDURO | $96M | $35M | +175.2% |
| GIAPREZA | $81M | $65M | +23.1% |
| XERAVA | $22M | $22M | -0.8% |
| ZEVTERA | $1M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Angiotensin II Small moleculeMarketedNCT03431077 | Catecholamine-resistant Hypotension (CRH) | Phase 2 | COMPLETED | 2 | Apr 14, 2018 |
Clinical Trial Results
Readouts, endpoints and source filings for every INVA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| zoliflodacin | uncomplicated gonorrhea | Phase 3 | 2023-11-02 | primary endpoint result: non-inferior to the comparator arm; point estimate: 5.3%; confidence interval: 95% confidence interval: 1.4%, 8.7%; cure rate: >90%Read More | Zoliflodacin Phase 3 clinical trial topline dataRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Basso StephenOfficer (Chief Financial Officer) | Disposition | -559 88,571 held | $22.24 | 05/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INVA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in INVA for Q2 2026. | ||||
INVA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INVA ranks across every disease it competes in
Competitive Position is a premium feature
See how INVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINVA News
INVAInnoviva to Participate in Upcoming Investor Conferences
Innoviva, Inc. (NASDAQ: INVA) has announced its participation in several upcoming investor conferences in September, including Citi's 2026 Biopharma Back to School Conference. This engagement highlights the company's commitment to investor relations and showcases its diversified portfolio in biopharmaceuticals and healthcare assets. The participation may enhance Innoviva's visibility in the market.
Read more →INVAInnoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
Innoviva Specialty Therapeutics has announced that three of its infectious disease therapies—XACDURO, ZEVTERA, and NUZOLVENCE—have been designated as finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award. This recognition highlights the company's commitment to developing effective treatments for infectious diseases and marks the third consecutive year of nominations.
Read more →INVAInnoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
Innoviva, Inc. announced its financial results for the second quarter of 2026, showcasing strong performance and highlighting key corporate achievements. The company continues to develop its diversified biopharmaceutical portfolio, particularly in critical care and infectious disease through its Innoviva Specialty Therapeutics platform. This positive outlook reflects the company's strategic investments and growth.
Read more →INVANortiva Bio Launches to Develop Long-Acting Oral Medicines
Nortiva Bio has launched as a clinical-stage biopharmaceutical company focused on developing long-acting oral medicines through its proprietary LYNX drug delivery platform. The platform aims to convert daily medications into monthly doses, enhancing efficacy and patient adherence. Nortiva's lead program is a once-monthly oral contraceptive supported by a grant from the Gates Foundation, addressing significant unmet needs in family planning.
Read more →INVAInnoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets
Innoviva Specialty Therapeutics has announced a distribution and licensing agreement with Dr. Reddy’s for XACDURO® in select international markets. This agreement aims to enhance the availability of XACDURO® in these regions. Further details regarding the specific markets and terms of the agreement were not disclosed.
Read more →INVAInnoviva to Participate in Upcoming June 2026 Investor Conferences
Innoviva, Inc. announced its participation in two investor conferences in June 2026, including the Goldman Sachs 47th Annual Global Healthcare Conference and BTIG Infectious Disease Day. The company will engage in a fireside chat and one-on-one meetings to discuss its diversified biopharmaceutical portfolio and strategic investments. A live webcast of the Goldman Sachs event will be available on their website.
Read more →INVAInnoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
Innoviva has reported its financial results for the first quarter of 2026, highlighting recent progress made by the company. Specific details regarding financial performance and strategic advancements were not disclosed in the article. The report emphasizes the company's ongoing efforts and developments in the biopharma sector.
Read more →INVAInnoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
Innoviva reported strong financial results for Q4 and the full year 2025, with revenues exceeding $400 million and net income surpassing $270 million. The company achieved significant growth in its IST product sales, driven by FDA approval of NUZOLVENCE for gonorrhea treatment. A $125 million share repurchase program was also initiated, highlighting confidence in future growth.
Read more →INVAInnoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Innoviva, Inc. will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The event will feature a fireside chat with management, accessible via a live webcast. Innoviva is known for its diversified portfolio, including royalties from respiratory assets and innovative healthcare solutions.
Read more →INVAU.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
The FDA has approved NUZOLVENCE (zoliflodacin), a first-in-class, single-dose oral antibiotic for treating uncomplicated urogenital gonorrhea in adults and adolescents. This approval is based on the largest Phase 3 clinical trial for a new gonorrhea treatment, demonstrating effectiveness against drug-resistant strains. NUZOLVENCE offers a convenient alternative to current injectable therapies, addressing significant public health challenges posed by rising antibiotic resistance.
Read more →INVAInnoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
Innoviva, Inc. reported strong financial results for the third quarter of 2025, showcasing $63.4 million in revenue from its royalties portfolio and achieving a 52% year-over-year growth in U.S. net product sales. The company is optimistic about the early market reception for its recently launched antibiotic, ZEVTERA, and is preparing for the upcoming PDUFA date for its investigational drug zoliflodacin. Additionally, Innoviva announced a $125 million share repurchase program, which underscores its confidence in future growth and shareholder value.
Read more →INVAInnoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
Innoviva, Inc. reported strong financial results for the second quarter of 2025, showcasing a robust royalties portfolio that generated $67.3 million in revenue. The company achieved U.S. net product sales of $29 million, reflecting a significant 54% growth compared to the previous year. The acceptance of the zoliflodacin NDA by the FDA with a Priority Review is a notable regulatory milestone, with a target action date set for December 15, 2025. Additionally, Innoviva launched ZEVTERA, marking a significant advancement in the treatment of MRSA-related infections.
Read more →INVAInnoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress
Innoviva, Inc. reported its financial results for the first quarter of 2025, showcasing a solid performance with $61.3 million in revenue from its royalty platform. The company experienced a 52% year-over-year increase in net product sales attributed to its therapeutic products. Key developments include the NDA filing for zoliflodacin and the expected commercial launch of ZEVTERA by mid-2025. However, despite the strong sales growth, Innoviva also reported a net loss of $46.6 million for the quarter, raising concerns regarding market volatility.
Read more →INVAFourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress Core royalty platform continues to deliver
Innoviva, Inc. (NASDAQ: INVA) reported its fourth quarter and full year 2024 financial results, showcasing a robust performance with significant revenue growth from its core royalty platform and specialty therapeutics business. The company achieved U.S. net product sales of $24.9 million for the fourth quarter, reflecting a 47% increase compared to the previous year. Innoviva also highlighted its acquisition of exclusive U.S. rights to ZEVTERA, which is set to launch in mid-2025. CEO Raifeld expressed optimism about continued growth in 2025, supported by strong financial positioning and a promising product pipeline.
Read more →INVAInnoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress Core royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth Innoviv
Innoviva, Inc. reported robust financial results for the third quarter of 2024, highlighting increases in revenue from its core royalty platform and commercial products. GSK royalties reached $60.5 million with a 6% increase year-over-year. The company's specialty therapeutics segment, including products like GIAPREZA and XACDURO, saw impressive growth, with net product sales climbing to $19.7 million, a 68% increase compared to the previous year. Looking ahead, Innoviva plans to submit a New Drug Application for zoliflodacin in early 2025.
Read more →INVAInnoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress Core royalty platform continued strong performance, receiving GSK royalties of $67.2 million Innoviva Specialty Therapeutics' (IS
Innoviva, Inc. reported its financial results for the second quarter of 2024, highlighting robust growth across its royalty portfolio and commercial products. The company achieved significant revenue with $67.2 million in royalties from GSK and a 38% year-over-year increase in net product sales, totalling $21.7 million. Additionally, key products like XACDURO received recognition in treatment guidelines, indicating their importance in critical care. However, Innoviva also faced a net loss for the quarter, raising concerns about future profitability amidst increasing expenses.
Read more →INVACorporate Presentation May 2024 Forward - looking statements The information in this presentation contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Secti
Innoviva's corporate presentation details forward-looking statements regarding its strategy, operations, and financial positions. The company highlights its cashflow-positive royalty business, which derives from widely used respiratory products, alongside a robust therapeutics platform. However, the presentation also emphasizes significant risks and uncertainties that may impede achieving projected goals. These include potential declines in future royalties and the timing of product commercialization.
Read more →INVAInnoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress Core royalty platform on track; receiving GSK royalties of $61.9 million Achieved net product revenues of $19.1 million, represent
Innoviva, Inc. reported its financial results for the first quarter of 2024, showcasing a robust performance driven by a significant increase in royalties and product revenues. The company generated net product revenues of $19.1 million, marking a 66% growth compared to the previous year. Additionally, the positive Phase 3 trial results for zoliflodacin emphasize the potential of its pipeline products. Innoviva plans to submit a New Drug Application for zoliflodacin in early 2025 and continues to focus on enhancing shareholder value through prudent investments and cost discipline.
Read more →INVAInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress Core royalty platform on track; received GSK royalties of $69.6 million for fourth quarter Achieved net product rev
Innoviva, Inc. reported its financial results for Q4 and full year 2023, showcasing significant achievements including a 35% year-on-year growth in product revenues. The company successfully launched XACDURO for Acinetobacter infections and reported positive Phase 3 data for the oral drug zoliflodacin. Innoviva ended the year with over $275 million in cash and receivables, reinforcing its strong financial position. The company's leadership emphasizes a focus on driving long-term shareholder value through disciplined financial strategies and innovative therapeutics.
Read more →About Innoviva, Inc.
Headquarters1350 OLD BAYSHORE HIGHWAY, BURLINGAME, CA, 94010
BIOPHARMAWATCH ELITE PLUS
Trade the next INVA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime